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Abstract
Background: Hematological malignancies (HM) are a public health problem. The pattern and distribution of
diagnosed hematological cancers vary depending on age, sex, geography, and ethnicity suggesting the
involvement of genetic and environmental factors for the development of these diseases. To our knowledge, there
is no published report on HM in the case of Eastern Morocco. In this report we present for the first time the overall
pattern of HM for this region.
Methods: Retrospective descriptive study of patients diagnosed with HM between January 2008 and December
2012 in three centres in Eastern Morocco providing cancer diagnosis, treatment or palliative care services. The FAB
(French-American-British) classification system has been taken into account in the analysis of myeloid and lymphoid
neoplasms.
Results: In this study, a total of 660 cases of HM were registered between January 2008 and December 2012.
Overall, 6075 cases of cancers all sites combined were registered during this study period, indicating that HM
account for around 10.9 % (660/6075) of all cancers recorded. Among the 660 registered cases of HM, 53 % were
males and 47 % were females, with a male to female ratio of 1.1. Thus, overall, men are slightly more affected with
HM than women. By contrast, a female predominance was observed in the case of Hodgkin’s lymphoma (HL),
myeloproliferative neoplasms (MPN), acute myeloid leukemia (AML) and the myelodysplastic syndrome (MDS). HM
occur at a relatively young age, with an overall median age at diagnosis of 54 years. Non-Hodgkin’s lymphoma
(NHL) was the most common HM accounting for 29.7 % of all HM, followed by HL, MPN, multiple myelomas
(MM), chronic lymphocytic leukemia (CLL), AML, MDS, acute lymphoblastic leukemia (ALL), and Waldenström
macroglobulinemia (WM). The majority of HM cases have been observed among patients aged 60 years and
over (40.4 % of HM). Among this age group, NHL was the most common HM. In adolescents, HL was the
most frequent HM.
Conclusions: This study provided for the first time the pattern and distribution of HM in Eastern Morocco.
Our findings justify the need to establish a regional cancer registry as a first step in blood cancer control
in Eastern Morocco.
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Background
The HM are a group of cancers that arise from a malig-
nant transformation of cells of the bone marrow or the
lymphatic system [1]. Several classification systems have
been developed over the past several years to subdivide
the HM by relevant clinical and biological means. These
classifications facilitate the recognition of HM and
therefore refine our ability to diagnose and treat these
cancers. Moreover, they enable the use of the same def-
inition of a specific hematopoietic neoplasm, so that data
comparison between studies is possible [2]. These classi-
fications have been updated since the early 1970s, and in
2001 the World Health Organization (WHO) published
a classification of tumours of the hematopoietic and
lymphoid tissues. This 2001 WHO classification was the
first worldwide consensus classification on hematological
tumours and was based on multiple information, such as
clinical, morphologic, biologic, immunophenotypic and
genetic features [3, 4]. In 2008, the WHO published a
new classification for hematopoietic and lymphoid neo-
plasms in conjunction with the Society for Hematopathol-
ogy and the European Association of Hematopathology
[3, 5]. This 4th edition of the WHO classification has
refined the 2001 classification on the basis of new
and cumulative experimental evidence [2, 5–11]. It in-
cludes new criteria for the recognition of some previously
described neoplasms and information about new entities
that have been defined mainly by genetic mutations that
have been characterized only recently [5, 6, 11].
There are two major groups of HM according to their
cell lineage: myeloid and lymphoid [7, 11]. Lymphoid
neoplasms are a very varied group and the common
subgroups are: NHL, HL, MM, WM, ALL, and CLL.
Myeloid neoplasms are represented mainly by MPN,
MDS and AML [5].
According to the most recent data, HM are estimated
to represent about 6.5 % of all cancers worldwide in
2012 [12]. In the same year, NHL represented 2.7 % of
all cancers and 2.4 % of all deaths from cancer world-
wide. Leukemia accounted for 2.5 % of all cancers and
3.2 % of all deaths. MM represented 0.8 % of all cancers
and 1.0 % of cancer deaths, while HL represented 0.5 %
of all cancers and 0.5 % of cancer deaths [12]. The
incidence of HM varies from one country to another.
It varies with geography, age and ethnicity, suggesting
the involvement of different etiological factors for
these diseases.
In Morocco, there is no national database on
hematological cancers, with the exception of some
basic data found in the population-based cancer regis-
tries of Rabat and Casablanca [13–15]. In Eastern
Morocco, there is no population-based cancer registry or
published epidemiology report on HM. Therefore, in this
study, we present for the first time the epidemiological
aspects of HM in Eastern Morocco. Analysis of their
distribution and their relative frequency compared to all
cancers in this region is also conducted.
Methods
Eastern Morocco is located in the north east of the
Kingdom of Morocco, and is the third largest region of
the Kingdom. According to the High Commission for
Planning (HCP), Eastern Morocco had a population of
over 2 million in 2013. The population is mainly urban
(67 % vs. 33 % rural) and young, nearly 6 out of 10
people are under 30 years [16]. Our retrospective study
was carried out in three centres: (1) Al-Farabi Regional
Hospital (ARH) with its hematology and internal medi-
cine units, which typically manage HM cases. (2) The
Boussif Diagnostic Center (BDC), which also diagnoses
HM cases. (3) Hassan II Regional Oncology Center
(ROC), which normally manages all solid cancer cases.
The study population consists of all patients diagnosed
with cancer at the participating centres between January
2008 and December 2012. Among these, all cases of HM
have been retrieved and reviewed carefully. For these
cases, the data collected included details such as name,
gender, age, place of residence, date of diagnosis, and
type of HM. We have encountered some practical diffi-
culties related to data collection since there is no
methodic and effective system for data recording at the
participating centres. For example, the same patient
happens to be registered at the same center with slightly
different names. So, before starting the analysis of the
actual data, we proceeded to the elimination of duplicate
cases. This step was necessary to avoid overestimating
the actual case of diagnosed cancers.
The FAB (French-American-British) classification sys-
tem has been taken into account in the analysis of myeloid
and lymphoid neoplasms [17–19]. This classification was
used instead of the 2008 WHO classification because of
the lack of immunophenotypic, cytogenetic and molecular
data necessary for the 2008 WHO classification. Data
collection was performed on Excel. Statistical analysis was
performed using SPSS software version 21.0. For the Chi-
squared test, the results are considered significant when p
(degree of significance) is less than 0.05, very significant
when p < 0.01 and highly significant when p < 0.001.
In this retrospective study, obtaining informed consent
was not possible. So, we were granted a waiver of
consent by the Ethical Review Committee, and patient
records/information was anonymized and de-identified
prior to analysis. The study was approved by the Ethic
Committee of the Faculty of Medicine and Pharmacy of
Casablanca under the number 41/14. The authorization
for personal data processing was obtained from the Na-
tional Commission of control of Personal Data Protection
under the number A-RS-280/2014.
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Results
In this study, 660 cases of hematological neoplasms were
registered between January 2008 and December 2012 in
the three participating centres. Overall, 6075 cases of
cancers all sites combined were registered in these
centres, indicating that HM account for around 10.9 %
(660/6075) of all cancers recorded (Table 1). Lymphoid
neoplasms were more common with 8.4 % of all cancers,
and myeloid neoplasms accounted for 2.2 % of all
cancers (Table 1). NHL was the most frequent HM
(3.2 % of all cancer cases), with a median age of 55 years.
HL was the second most common HM (1.7 %, median
age 34 years), followed respectively by MPN (1.4 %,
median age 53 years), MM (1.4 %, median age
63.5 years), CLL (0.6 %, median age 67 years), AML
(0.5 %, median age 42.5 years), MDS (0.3 %, median age
62 years), ALL (0.3 %, median age 48 years), and finally
WM (0.1 %, median age 46.5Years) (Table 1). The
median age difference observed between the various
types of HM was statistically significant (p < 0.05).
HM all types combined were slightly more common in
men than in women with a male to female ratio of 1.1
(Table 1). This slight male predominance was statistically
significant (p < 0.05). In males, NHL was the most
frequent HM with 32 % of all male hematological can-
cers, followed respectively by HL (14.4 %), MM (12.7 %),
MPN (9.8 %), CLL (8.1 %), AML (4.3 %), ALL (2.6 %),
and finally MDS (2.3 %) (Table 1). In females, NHL was
also the most frequent HM with 27.2 % of all female
hematological cancers followed respectively by HL
(17.6 %), MPN (16 %), MM (12.1 %), AML (5.4 %), MDS
(3.8 %), CLL (3.2 %), and finally ALL (2.2 %). Only 4
cases of WM were registered in our study and were all
female cases (Table 1).
In our study, the overall median age at diagnosis for
all HM combined was 54 years (Table 1). As with most
cancers, the probability of being diagnosed with a HM
increases markedly with age. However, unlike many
other cancers, HM can be diagnosed at any age. Among
the 660 registered cases of HM, the age at diagnosis was
available for 651 cases. Of these, 51 cases were diag-
nosed in patients under 20 years of age, 119 cases in
patients aged 20-39 years, 218 cases aged 40-59 years,
and 263 cases were observed in patients aged 60 and
over. The distribution of HM varies according to age
group, and this difference was statistically significant
(p < 0.05).
Indeed, in patients under 20 years of age, HL was the
most common with 39.2 % of HM diagnosed in this age
group, followed respectively by NHL (29.4 %), AML
(5.9 %), MPN (3.9 %); and ALL, MDS and MM (equally
represented with 2 %) (Fig. 1, Additional file 1). In this
age group, there is a male predominance with a male to
female ratio of 1.8 (Fig. 1).
In young adults aged 20-39 years, HL was also the
most frequent with 31.9 % of HM diagnosed in this age
group, followed respectively by NHL (18.5 %), MPN
(13.5 %), AML (8.4 %), ALL and MM (equally repre-
sented with 4.2 %), CLL (1.7 %), MDS and WM (equally
represented with 0.8 %) (Fig. 1, Additional file 1). In this
age group, there is a slight male predominance with a
male to female ratio of 1.2 (Fig. 1).
In adults aged 40-59 years, NHL was predominant
with 36.2 % of HM diagnosed in this age group, followed
Table 1 Distribution pattern, median age at diagnosis and male to female ratio of hematological malignancies in Eastern Morocco
All patients Males Females
N. % of all cancers % of HM Median age M/F N. % of HM N. % of HM
All HM 660 10.9 100 54 1.1 347 100 313 100
Lymphoid neoplasm 507 8.4 76.8 55 1.2 281 81.0 226 72.2
NHL 196 3.2 29.7 55 1.3 111 32.0 85 27.2
HL 105 1.7 15.9 34 0.9 50 14.4 55 17.6
MM 82 1.4 12.4 63.5 1.2 44 12.7 38 12.1
CLL 38 0.6 5.8 67 2.8 28 8.1 10 3.2
ALL 16 0.3 2.4 48 1.3 9 2.6 7 2.2
WM 4 0.1 0.6 46.5 a 0 0 4 1.3
Othersb 66 1.1 10 - - 39 11.2 27 8.6
Myeloid neoplasm 136 2.2 20.6 53 0.7 57 16.4 79 25.2
MPN 84 1.4 12.7 53 0.7 34 9.8 50 16.0
AML 32 0.5 4.9 42.5 0.9 15 4.3 17 5.4
MDS 20 0.3 3.0 62 0.7 8 2.3 12 3.8
Unspecified HM 17 0.3 2.6 - - 9 2.6 8 2.6
HM hematological malignancies, N number of cases; % of all cancers: Percentage amongst all cancers; % of HM: percentage amongst hematological malignancies;
a: all patients were females; b: Other lymphoid neoplasms; M/F male to female ratio; -: not applicable
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respectively by MPN (17.0 %), MM (11.9 %), HL (9.6 %),
CLL (5.0 %), AML (4.6 %), MDS (2.8 %), ALL (1.8 %)
and WM (0.9 %) (Fig. 1, Additional file 1). In this age
group, there is a male predominance with a male to
female ratio of 1.3 (Fig. 1).
In older individuals over 60 years old, NHL was the
most common with 29.3 % of HM, followed respectively
by MM (19.0 %), MPN (11.0 %), CLL (9.5 %), HL
(9.1 %), MDS (4.6 %), AML (3.4 %), ALL (2.3 %) and
WM (0.4 %) (Fig. 1, Additional file 1). In this age group,
there is a female predominance with male to female
ratio of 0.9 (Fig. 1). The sex ratio difference between the
various age groups was statistically significant at (p < 0.05).
In the group of lymphoid neoplasms, NHL was the
most common disease with 38.7 % of all lymphoid
neoplasms, followed respectively by HL (20.7 %), MM
(16.2 %), CLL (7.5 %), ALL (3.2 %), and WM (0.8 %)
(Fig. 2a). Among the 196 NHL cases recorded during
the study period, only 46 cases had information on
the histological type available. The analysis of these
showed that the diffuse large cell lymphomas are the
most common (45.7 %), followed respectively by dif-
fuse small cell lymphomas (15.2 %), follicular lymph-
oma (8.7 %) and cutaneous lymphoma (4.3 %)
(Fig. 3). Analysis of ALL showed that L2 was the pre-
dominant FAB subtype with 67 % of ALL, followed
respectively by L3 (22 %) and L1 (11 %) (Fig. 4a). For
myeloid neoplasms, MPN were the most frequent
with 61.8 % of all myeloid neoplasms, followed by
AML (23.5 %) and MDS (14.7 %) (Fig. 2b). Among
FAB subtypes of AML, the commonest was M2
(46 %) followed by M3 and M5 (17 % each), M1
(8 %), and M0, M4 and M6 (4 % each) (Fig. 4b).
Discussion
To our knowledge, this is the first epidemiological study
on HM in Eastern Morocco. It was carried out using
data collected from three different tertiary health care
facilities available for management of cancer patients. It
presents for the first time the relative frequency of
several types of HM compared to all cancers in this
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Fig. 2 a. Distribution of NHL, HL, MM, CLL, ALL and WM amongst all lymphoid neoplasms (Others: Other lymphoid neoplasms). b. Distribution of
MPN, AML and MDS amongst all myeloid neoplasms in Eastern Morocco, 2008-2012
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of all cancers. This result is similar to those of Rabat and
Casablanca [13, 15, 20]. In The United-States, HM
accounted for 9,3 % of all cancers [21], which is similar
to our data, but a much higher percentage was observed
for hematological cancers in other studies: (18.05 % in
Nigeria, 20 % in Iran and 24.8 % in Yemen) [22–25].
We found that lymphoid neoplasms are the most
common, accounting for 76.8 % of all HM. This result
is similar to those observed in cancer registries of
Rabat, and Casablanca [13, 15]. Lymphoid neoplasms
are also predominant in North America, Australia,
Europe, Africa and Asia [26–30].
Sex-ratio and age of HM in Eastern Morocco
Sex-ratio of HM
We found that overall men are slightly more affected with
HM than women, with a male to female ratio of 1.1
(p < 0.05). Such a finding is similar to those reported
in France and in the United Kingdom, where male to
female ratio was 1.2 and 1.3, respectively [28, 30]. How-
ever, the sex ratio was much higher in Bangladesh and
Senegal with a male to female ratio of 2.2 and 1.6, re-
spectively [29, 31]. In the population of Rabat, males were
also much more affected than females with HM [15, 20].
Although there is a slight male predominance among
HM overall, the sex ratio varied between age groups. In
our study, a strong male predominance was observed in
the age group 0-19 years, with a male to female ratio of
1.8. A similar result was observed in the Casablanca
registry for this age group, with a male to female ratio of
2.5 [13]. Several studies have shown that in developing
countries HM in children often affect boys more than
girls [32]. For the age groups 20-39, 40-59 and 60 years
and over, the female to male ratio was 1.2, 1.3 and 0.9,
respectively. This underlines the importance of the sex
variable in the development of HM, as has been noted
previously [33]. Further research is needed to under-
stand the sex differences observed in Eastern Morocco.
Median age at diagnosis of HM
Our study revealed that HM in Eastern Morocco occur
in adult population with an overall median age at diag-
nosis of 54 years (mean age 51.96 years). In Western
countries, the HM usually affect older people. For
example, in the United Kingdom, the median age at
diagnosis was 70.6 years [28]. However, in Asia, HM
usually affect the younger population. For example, in
Bangladesh, the median age was 42 years [31]. Thus, the
median age at diagnosis of HM in Eastern Morocco is
younger than that found in Western countries, but it is
higher than that in Asia. It is important to note that the































Fig. 4 a. Distribution of ALL subtypes according to FAB classification. b. Distribution of AML subtypes according to FAB classification in Eastern
Morocco, 2008-2012
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lower, given the under-representation of children in this
study because childhood cancer cases are normally
treated in other services. Several factors may be involved
in the occurrence of HM at relatively young ages such as
shorter life expectancy, younger population, genetic and
environmental factors. Further studies are needed to
confirm the role of these factors in the young age of HM
in Eastern Morocco.
HM in patients aged over 60 years
In our study, the majority of hematological cancer cases
have been observed among patients aged 60 years and
over (40.4 % of MH). This result is predictable since
cancer is triggered after several genetic mutations that
accumulate with age [34, 35]. In this age group, there
was a female predominance with a male to female ratio
of 0.9. The greater longevity of women might be partly
responsible for this female predominance among elderly
patients. In this age group, NHL was the most common
(29.3 % of HM), followed respectively by MM (19.0 %),
MPN (11.0 %), CLL (9.5 %), HL (9.1 %), MDS (4.6 %),
AML (3.4 %), ALL (2.3 %) and WM (0.4 %). The higher
prevalence of HM in this age group justifies the need
to develop effective programs to improve the mana-
gement of hematological malignant diseases in the
elderly, especially when they are associated with
comorbidity factors [36, 37].
HM in adolescents
In adolescents (15-19 years age group) lymphomas were
predominant and accounting for 64.4 % of HM (HL-
33.3 %, NHL-31.1 %). Lymphomas were also the most
common cancers among adolescents in Europe, North
America, Middle East, Algeria and several African coun-
tries [38–42]. However, in Asia and Latin America, leu-
kemias were the most frequent cancers in adolescents
[31, 42, 43]. The distribution of lymphomas in our study
is comparable to that in Europe, North America and
Israel where HL is more frequent than NHL [38, 42].
However, in Algeria and in most African countries, HL
is less common than NHL [38–42]. Infection with
Epstein-Barr virus (EBV) has been associated with most
cases of NHL or HL [44–47]. Other risk factors have
been associated with HM in children such as diet, pater-
nal smoking, genetic and environmental factors, but the
results are inconclusive [48–50]. Further studies are
needed to understand the reasons for this distribution of
HM in adolescents in Eastern Morocco.
Features of lymphoid neoplasms in Eastern Morocco
Non-Hodgkin’s lymphoma
In this study, NHL was the most frequent common
HM. NHL was also the most frequent HM in cancer
registries of Rabat, Casablanca and other African
countries [13, 15, 20, 23, 51, 52]. In developed coun-
tries, NHL is also the most prevalent type of HM,
with the highest incidence in the United States,
Australia, New Zealand and Europe [53]. In Asian
countries like Japan, Korea and Yemen, NHL is also
the commonest cancer among HM. However, in other
countries including India and Bangladesh, leukemia
cases were the most frequent HM [12, 31, 43, 53, 54].
NHL was more common in men than in women with
a male to female ratio of 1.3. Such a finding is similar to
that reported in Casablanca, where male to female ratio
was 1.53 [13, 55]. However, the sex ratio was much
higher in Rabat with a male to female ratio of 2.25 [20].
The frequency of NHL increases with advancing age, but
affected equally adults and elderly (Fig. 5). We observed
that 7.8 % of all NHL were under 20 years, 37.9 % were
below age 50 and 39.9 % were over 60 years (Fig. 5,
Additional file 1). This age distribution of NHL is similar
to that observed in Casablanca where patients under 20
accounted for 8 % of all NHL cases, patients younger
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60 years accounted for 42.1 % [13, 55]. In our study we
found that diffuse large cell lymphoma was the most
common form of NHL (45.7 %), which is consistent with
the Rabat and Casablanca studies, which also reported a
predominance of diffuse large cell lymphoma with
46.9 % and 50.1 %, respectively [20, 55]. Diffuse small
cell lymphoma constituted 15.2 % of NHL, which is
lower compared to Casablanca (19.2 %) [55]. Follicular
lymphoma constituted 8.7 %, which is higher than the
figure suggested by the Rabat study (6.2 %) [20]. Cutane-
ous lymphoma constituted 4.3 % of NHL, which is com-
parable to that in Casablanca (3.3 %), and Rabat (6.2 %)
[20, 55]. Further extensive study is necessary to under-
stand this difference in the distribution of the various
form of NHL between Eastern Morocco and other
regions of Morocco.
Hodgkin’s lymphoma
In this study, HL was the second most common blood
cancer after NHL, accounting for 15.9 % of all HM. This
frequency is lower than that observed in the cancer
registry of Casablanca (between 17 % and 21.4 %), but it
is higher than those observed in Rabat (10.4 %), United
States (5.87 %), and France (5 %) [20, 21, 30, 55, 56]. A
lower frequency was observed in other studies in Asian
countries including China, Japan, India, Korea and
Bangladesh [31, 57–60]. In our study, HL occurred in
people of all ages with a peak in young adults (36.9 % of
all patients with LH occurred in the age group 20-39
years) (Fig. 5, Additional file 1). In developed countries,
the age distribution of HL is bimodal, the first peak
occurs in young adults (20-34 years) and the second
peak in the older age group (55-74 years). In contrast, in
developing countries, the first peak occurs in children
(under 20), probably because of an earlier infection with
the Epstein-Barr virus in children living in those coun-
tries [61, 62]. Therefore, the age distribution of HL in
Eastern Morocco resembles that of developed countries
with a peak in young adults.
In our study, we found that women are slightly more
affected with HL than men, with a male to female ratio
of 0.9. Such a finding is far from that reported in other
studies, where HL is much more frequent in men than
in women with a male to female ratio between 1.5 and 2
[33, 63, 64]. In Casablanca and Rabat, it was reported
that HL affects males and females, with an equal ratio
[13, 20]. Additional studies are needed to better under-
stand these sex ratio differences.
Multiple Myeloma
MM is the fourth most common blood cancer in Eastern
Morocco, accounting for 12.4 % of all HM. This frequency
of MM is comparable to those in the United States (13 %),
France (13.7 %) and UK (10.5 %) [28, 30, 65]. We found
that men are slightly more affected with MM than
women, with a male to female ratio of 1.2, which is
consistent with other studies [33, 65, 66]. The frequency
of MM increases with advancing age: 1.2 % MM occurred
in children under 20 years, 6.1 % in young adults, 31.7 %
in adults and 61 % in patients aged 60 years and over
(Fig. 5, Additional file 1). The overall median age at diag-
nosis was 63.5 years, which is significantly higher as
compared to Asian countries where the median age is
around 55 years [31, 67], but it is lower as compared to
Western countries, where the median age is between 65
and 70 years [68].
Chronic lymphoid leukemia
In this study, CLL constituted 5.8 % of all HM. This fre-
quency is higher as compared to those observed in Asian
countries [31, 69, 70], and lower as compared to what
has been reported in Western countries [27, 28, 30, 71].
In the US, the incidence of CLL is lower among Asians
and African-Americans as compared to Caucasians [72].
Therefore, multiple factors may play an important role
in the development of CLL, including genetic and
environmental factors [71–73].
We found that the median age at diagnosis for CLL
was 67 years. This result is intermediate between the
results found in Western countries (median age of 70-72
years) and Asia (median age of 59-60 years) [28, 30, 31,
70, 74]. We found that the frequency of CLL increases
with advancing age. Indeed, no cases of CLL have been
observed in children under 20 years, 5.3 % of CLL
occurred in young adults, 28.9 % in adults and 65.8 %
in patients aged 60 years and over (Fig. 5, Additional file 1).
There is a male predominance among CLL, with a male to
female ratio of 2.8, which is in accordance with studies
reported from India (sex ratio of 3), Bangladesh (sex ratio
of 2.9), Ethiopia (sex ratio of 3.6), and Western countries
(sex ratio of 1.5–2) [30, 31, 70, 71, 75].
Acute lymphocytic leukemia
ALL constituted 2.4 % of all HM. This frequency is simi-
lar to those reported from France (2.7 %), UK (2 %) and
United States (3.84 %) [21, 28, 30], but lower as com-
pared to those observed in Asian countries such as
Yemen (4 %) and Bangladesh (14.1 %) [22, 31]. ALL is
generally most common in childhood and its age inci-
dence curve is bimodal, with a peak in childhood and
another peak in old age [30, 63, 76]. Our study showed a
different profile, with the first peak occurring in the 20-
39 years age group, and the second peak in old age
(Fig. 5, Additional file 1). Only 6.3 % of ALL was ob-
served in children aged under 20 years old, and thus the
childhood peak was absent. This difference could be ex-
plained by the under-representation of children in our
study, since children HM are usually treated in other
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services. We also found that L2 was the predominant
FAB subtype (67 %), followed by L3 (22 %) and L1
(11 %), which is consistent with the age distribution of
ALL in our study since L2 is more often observed in
adults and most childhood cases are of subtype L1 [77].
Features of myeloid neoplasms in Eastern Morocco
Myeloproliferative neoplasms
In our study, MPN constituted 12.7 % of all HM. This
frequency is comparable to that reported in France
(11 %), and the UK (9 %) [28, 30]. We found that MPN
were more common in women than in men, with a male
to female ratio of 0.7. A female predominance was also
observed in the United Kingdom (sex ratio of 0.8) and
France (sex ratio of 0.94) [28, 30]. We also found that
MPN were more common in adults and elderly but also
affected younger patients (Fig. 5, Additional file 1). The
mean age of diagnosis was 52.8 years, which is lower
than the one observed in France (65) [30]. The youn-
ger age phenomenon of HM was discussed earlier in
this discussion.
Acute myeloid leukemia
AML constituted 4.9 % of all HM. This frequency is
comparable to that in Yemen (4 %), but it is lower than
those reported in France (7 %), UK (6.68 %), United
States (12 %) and Bangladesh (28.3 %) [21, 22, 28, 30,
31]. We found that AML is more common in women
than in men with a male to female ratio of 0.9 which is
different from what was found in other studies [28, 30,
31, 76, 78]. Our study showed that AML affected equally
young adults, adults and elderly (Fig. 5, Additional file
1). However, in Western countries, AML generally af-
fects older people with a median age of 65-67 years [71,
79]. In France, for example, 60.6 % of AML was ob-
served in people aged 60 years and over [30]. A different
picture is observed in Asia, where AML affects young
adults with a median age at diagnosis of 30 years in
India and 35 in Bangladesh [31, 80]. In our study, the
distribution of AML according to the FAB classification,
has revealed that M2 was the predominant FAB subtype
(46 %), followed by M3 and M5 (17 %), M1 (8 %),
M0, M4 and M6 (4 %). This distribution was compar-
able to that reported in China [81]. The predomin-
ance of M2 was also observed in Iran, India,
Germany, USA and Singapore [82–86].
Myelodysplastic syndrome
MDS constituted 3 % of all HM, which is lower to what
was reported in Bangladesh (4.5 %), UK (6 %), and
France (12.8 %) [28, 30, 31]. We found that MDS
affected elderly with a median age of 62 years, and 60 %
of the MDS patients aged over 60 years (Fig. 5,
Additional file 1). This result is similar to that reported
in Western countries where MDS typically affects elderly
people with a median age at diagnosis between 60 and
70 years [28, 30]. However, in Asian countries, MDS
typically affects people who are much younger [31, 43,
80]. The median age was 46.1 years in India and 57 years
in Bangladesh [31, 87]. We found that MDS is more
common in women than in men with a male to female
ratio of 0.7, which is different from what was found in
other studies. For example, the sex ratio was 1.38 in
France, 2 in UK, and 1.9 in Bangladesh [28, 30, 31].
Conclusion
This study provided for the first time the pattern and
distribution of HM in Eastern Morocco. HM occur at a
relatively young age, with an overall median age at diag-
nosis of 54 years. Overall, men are slightly more affected
with HM than women, with a male to female ratio of
1.1. NHL was the most common HM accounting for
29.7 % of all HM, followed by HL, NMP, MM, CLL,
AML, MDS, ALL, and WM. The majority of HM cases
have been observed among patients aged 60 years and
over (40.4 % of MH). In adolescents, HL was the most
frequent HM.
Our findings justify the need to establish a regional
cancer registry as a first step in blood cancer control in
Eastern Morocco. Further studies are necessary to better
understand and develop a more effective program
aiming at controlling and preventing the spread of blood
cancers in Eastern Morocco.
Additional file
Additional file 1: Includes two tables: (Table S1) showing the
distribution and male to female ratio of hematological malignancies by
age group in Eastern Morocco for the study period, and (Table S2) showing
the Age-group specific distribution of hematological malignancies in Eastern
Morocco, 2008-2012. (PDF 32 kb)
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